Copyright
©The Author(s) 2016.
World J Gastrointest Pathophysiol. Feb 15, 2016; 7(1): 117-124
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.117
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.117
Duodenal NETs – surgical treatment | |
≤ 1 cm | Local ressection (if possible) |
≥ 2 cm OR lymph nodes metastasis | Surgical ressection |
Potentially resectable hepatic metastases without distant metastases and no other significant comorbility | Palliative surgery |
Duodenal NETs – farmacological treatment | |
Functional duodenal NETs | Hormone suppression treatment |
Well-differentiated NETs | Systemic chemotherapy if advanced metastatic disease |
Poorly differentiated tumors | Combination chemotherapy – variable duration disease remission |
mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results | |
Metastatic or inoperable disease | Peptide receptor radionuclide therapy |
When all other treatment options fail | |
If positive octreoscan |
- Citation: Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol 2016; 7(1): 117-124
- URL: https://www.wjgnet.com/2150-5330/full/v7/i1/117.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v7.i1.117